CLINICAL_TRIALS
ClinicalTrials.gov record update
A Phase 1/2 Open-label Multicenter Study to Assess the Safety, Pharmacokinetics, and Anti-tumor Activity of GTAEXS617 in Patients With Advanced Solid Tumors
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT05985655
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-25T22:29:04.559344+00:00
- Published At
- 2026-04-23T00:00:00+00:00
- Record Updated At
- 2026-04-23
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Head and Neck Squamous Cell Carcinoma (HNSCC)", "Pancreatic Adenocarcinoma", "Non-small Cell Lung Cancer (NSCLC)", "Platinum-resistant High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (HGSOC)", "Hormone Receptor Positive [HR+] and Human Epidermal Growth Factor Receptor 2 Negative [HER2-] Breast Carcinoma", "Triple Negative Breast Cancer (TNBC)"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2026-04-23"- protocolSection.identificationModule.nctId
"NCT05985655"- protocolSection.identificationModule.officialTitle
"A Phase 1/2 Open-label Multicenter Study to Assess the Safety, Pharmacokinetics, and Anti-tumor Activity of GTAEXS617 in Patients With Advanced Solid Tumors"- protocolSection.statusModule.overallStatus
"RECRUITING"- protocolSection.designModule.phases
["PHASE1", "PHASE2"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
""
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.